Brookline Capital Markets Predicts Genelux Q3 Earnings

Genelux Corporation (NASDAQ:GNLX) – Brookline Capital Markets boosted their Q3 2026 earnings per share estimates for Genelux in a note issued to investors on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver now expects that the company will earn ($0.19) per share for the quarter, up from their previous estimate of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.80) per share. Brookline Capital Markets also issued estimates for Genelux’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.80) EPS and FY2027 earnings at ($0.59) EPS.

Genelux (NASDAQ:GNLX) last announced its earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01).

A number of other equities analysts have also commented on the company. Benchmark restated a “speculative buy” rating on shares of Genelux in a research note on Tuesday. Wall Street Zen downgraded shares of Genelux from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Genelux Stock Performance

NASDAQ:GNLX opened at $2.68 on Thursday. Genelux has a 52 week low of $2.29 and a 52 week high of $8.53. The firm’s 50-day simple moving average is $2.87 and its 200 day simple moving average is $2.77. The firm has a market cap of $121.24 million, a price-to-earnings ratio of -3.12 and a beta of 0.60.

Institutional Trading of Genelux

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning raised its position in Genelux by 4.7% in the 3rd quarter. Creative Planning now owns 46,108 shares of the company’s stock valued at $194,000 after buying an additional 2,084 shares during the last quarter. Raymond James Financial Inc. raised its position in Genelux by 22.6% in the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after acquiring an additional 5,333 shares during the period. Geode Capital Management LLC lifted its stake in Genelux by 1.8% in the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock valued at $915,000 after purchasing an additional 5,596 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Genelux during the 4th quarter valued at $48,000. Finally, GSA Capital Partners LLP purchased a new stake in Genelux during the second quarter valued at about $35,000. 37.33% of the stock is owned by institutional investors.

Insider Buying and Selling at Genelux

In other Genelux news, Director John W. Smither sold 12,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total value of $34,920.00. Following the completion of the sale, the director directly owned 91,403 shares in the company, valued at approximately $265,982.73. This trade represents a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Thomas sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $2.98, for a total value of $29,800.00. Following the completion of the sale, the director owned 472,784 shares of the company’s stock, valued at approximately $1,408,896.32. This represents a 2.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 25,868 shares of company stock worth $76,120. 7.50% of the stock is owned by insiders.

Genelux News Summary

Here are the key news stories impacting Genelux this week:

• Positive Sentiment: HC Wainwright modestly improved its Q4 2026 EPS forecast to a loss of $0.19 from a loss of $0.20. The firm also continues to project a potential transition to profitability, forecasting positive EPS of $0.61 in FY2028, $1.63 in FY2029 and $2.52 in FY2030.
• Neutral Sentiment: Brookline Capital Markets initiated quarterly FY2027 estimates ranging from a $0.10 loss per share in Q1 to a $0.19 loss in Q4. These projections indicate that Genelux is expected to remain unprofitable throughout FY2027, broadly consistent with the company’s development-stage profile and the current full-year consensus estimate of a $0.80 loss per share.
• Negative Sentiment: HC Wainwright lowered its FY2027 EPS forecast to a $0.77 loss from a $0.75 loss and reduced its Q3 2026 estimate to a $0.21 loss from a $0.20 loss. It also cut its long-term estimates for FY2028, FY2029 and FY2030 to $0.61, $1.63 and $2.52 per share, respectively, from $0.64, $1.69 and $2.61.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.